Literature DB >> 12804791

A decrease in interleukin-1 receptor antagonist expression in the prefrontal cortex of schizophrenic patients.

Kazuhiko Toyooka1, Yuichiro Watanabe, Shuji Iritani, Eiji Shimizu, Masaomi Iyo, Ryosuke Nakamura, Koue Asama, Takao Makifuchi, Akiyoshi Kakita, Hitoshi Takahashi, Toshiyuki Someya, Hiroyuki Nawa.   

Abstract

Interleukin-1 (IL-1) mediates psychological stress responses by regulating monoamine metabolism and secretion of corticotropin-releasing factor, and is therefore, implicated in various psychiatric diseases. To evaluate the contribution of IL-1 signaling to the brain pathology of schizophrenia, we measured protein and/or mRNA levels for IL-1beta and endogenous IL-1 receptor antagonist (IL-1RA) in the postmortem brain tissues of prefrontal and parietal cortex, putamen, and hypothalamus. Both protein and mRNA levels of IL-1RA were specifically decreased in the prefrontal cortex of schizophrenic patients, whereas IL-1beta levels were not significantly altered in all the regions examined. The IL-1RA decrease was not correlated with the dose of antipsychotics given to patients. There was no influence of this illness on protein levels for IL-1 receptor type 1 in the prefrontal cortex, either. In contrast, IL-1RA serum levels were increased in schizophrenic patients, especially in drug-free patients, as reported previously. These findings suggest that chronic schizophrenia down-regulates IL-1RA production the prefrontal cortex, irrespective of its impact on the periphery. IL-1RA reduction might reflect an immunopathologic trait of the prefrontal region in schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12804791     DOI: 10.1016/s0168-0102(03)00093-2

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  12 in total

Review 1.  Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?

Authors:  Henry Silver; Yael Chertkow; Orly Weinreb; Lena Danovich; Moussa Youdim
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

2.  Association study of MiRSNPs with schizophrenia, tardive dyskinesia and cognition.

Authors:  Jibin John; Triptish Bhatia; Prachi Kukshal; Puneet Chandna; Vishwajit L Nimgaonkar; Smita N Deshpande; B K Thelma
Journal:  Schizophr Res       Date:  2016-04-19       Impact factor: 4.939

3.  Measurement and comparison of serum neuregulin 1 immunoreactivity in control subjects and patients with schizophrenia: an influence of its genetic polymorphism.

Authors:  M Shibuya; E Komi; R Wang; T Kato; Y Watanabe; M Sakai; M Ozaki; T Someya; H Nawa
Journal:  J Neural Transm (Vienna)       Date:  2010-06-05       Impact factor: 3.575

4.  Neuromodulatory role of endogenous interleukin-1β in acute seizures: possible contribution of cyclooxygenase-2.

Authors:  Robert J Claycomb; Sandra J Hewett; James A Hewett
Journal:  Neurobiol Dis       Date:  2011-08-10       Impact factor: 5.996

5.  Effect of chronic treatment with perazine on lipopolysaccharide-induced interleukin-1 beta levels in the rat brain.

Authors:  Ewa Obuchowicz; Agnieszka Marcinowska; Lukasz Drzyzga; Jacek Wójcikowski; Władysława A Daniel; Zbigniew S Herman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-01       Impact factor: 3.000

6.  Maternal immune activation causes age- and region-specific changes in brain cytokines in offspring throughout development.

Authors:  Paula A Garay; Elaine Y Hsiao; Paul H Patterson; A K McAllister
Journal:  Brain Behav Immun       Date:  2012-07-25       Impact factor: 7.217

7.  Proteome Analysis of PC12 Cells Reveals Alterations in Translation Regulation and Actin Signaling Induced by Clozapine.

Authors:  Urszula Jankowska; Bozena Skupien-Rabian; Bianka Swiderska; Gabriela Prus; Marta Dziedzicka-Wasylewska; Sylwia Kedracka-Krok
Journal:  Neurochem Res       Date:  2021-05-23       Impact factor: 3.996

Review 8.  Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review.

Authors:  M O Trépanier; K E Hopperton; R Mizrahi; N Mechawar; R P Bazinet
Journal:  Mol Psychiatry       Date:  2016-06-07       Impact factor: 15.992

9.  Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies.

Authors:  C F M G van Kesteren; H Gremmels; L D de Witte; E M Hol; A R Van Gool; P G Falkai; R S Kahn; I E C Sommer
Journal:  Transl Psychiatry       Date:  2017-03-28       Impact factor: 6.222

10.  Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication.

Authors:  Andrea Schmitt; Thomas Bertsch; Heike Tost; Andrea Bergmann; Uwe Henning; Ansgar Klimke; Peter Falkai
Journal:  Neuropsychiatr Dis Treat       Date:  2005-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.